OF COUNSEL:

John E. Flaherty, Esq.

McCARTER & ENGLISH, LLP

Four Gateway Center

100 Mulberry Street

Dominick A. Conde, Esq.
Diego Scambia, Esq.
Gregory B. Sephton, Esq.

Newark, New Jersey 07102 FITZPATRICK, CELLA, HARPER &

Phone: (973) 622-4444 SCINTO

Facsimile: (973) 624-7070 1290 Avenue of the Americas

Attorneys for Plaintiffs

Attorneys for Plaintiffs

Warner Chilcott Laboratories Ireland Limited,

Phone: (212) 218-2100

Facsimile: (212) 218-2200

Warner Chilcott Company, LLC,

v.

Warner Chilcott (US), LLC and Attorneys for Plaintiffs

Manual Plantage Letter and Plantage Children Child

Mayne Pharma International Pty. Ltd Warner Chilcott Laboratories Ireland Limited,

Warner Chilcott Company, LLC and

Warner Chilcott (US), LLC

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

WARNER CHILCOTT LABORATORIES : Civil Action No.

IRELAND LIMITED, et al., : 2:09-cv-02073-WJM-MF

:

Plaintiffs, : (Consolidated for discovery purposes with:

: 2:08-cv-6304-WJM-MF : 2:09-cv-00228-WJM-MF

: 2:09-cv-00228-wJM-MF : 2:09-cv-01233-WJM-MF

MYLAN PHARMACEUTICALS INC. and : 2:10-cv-00511-WJM-MF)

MYLAN INC.,

: NOTICE OF MOTION FOR

Defendants. : PRELIMINARY INJUNCTION AND

: TEMPORARY RESTRAINING: ORDER AGAINST DEFENDANTS: MYLAN PHARMACEUTICALS INC.

: AND MYLAN INC.

Motion Date: September 19, 2011

Motion Date. September 19, 20.

: ORAL ARGUMENT REQUESTED

TO: ALL COUNSEL

PLEASE TAKE NOTICE that on September 19, 2011 at 10:00 a.m, or as soon

thereafter as counsel may be heard, Plaintiffs Warner Chilcott Company, LLC, Warner Chilcott

(US), LLC (collectively, "Warner Chilcott")¹, and Mayne Pharma International Pty. Ltd. (collectively, "Plaintiffs") will move before United States District Judge William J. Martini at the Martin Luther King, Jr. Building & U.S. Courthouse, 50 Walnut Street, Newark, New Jersey, for entry of a preliminary injunction against Defendants Mylan Pharmaceuticals Inc. and Mylan Inc., and those acting in concert with them, (collectively, "Mylan"), preliminarily enjoining Mylan from engaging in the commercial manufacture, distribution, use, marketing or sale of generic 150 mg doxycycline hyclate delayed release tablet products during the pendency of this injunction and until the Court has resolved all issues of validity and infringement relating to the patents-in-suit;

PLEASE TAKE FURTHER NOTICE that in conjunction with Plaintiffs' Motion for a Preliminary Injunction, Plaintiffs will seek that Mylan retract immediately in writing any offers for sale of generic 150 mg doxycycline hyclate delayed release tablet products made to any customers or potential customers;

PLEASE TAKE FURTHER NOTICE that in conjunction with Plaintiffs' Motion for a Preliminary Injunction, Plaintiffs will seek a temporary restraining order against Mylan effective September 27, 2011, temporarily restraining Mylan from engaging in the commercial manufacture, distribution, use, marketing or sale of generic 150 mg doxycycline hyclate delayed release tablet products until the Court's resolution of the preliminary injunction motion;

PLEASE TAKE FURTHER NOTICE that in conjunction with Plaintiffs' Motion for a Preliminary Injunction, Plaintiffs will seek a temporary restraining order against Mylan effective September 27, 2011, that Mylan retract immediately in writing any offers for sale of generic 150

¹ Warner Chilcott Laboratories Ireland Limited, originally named a Plaintiff, has been dissolved.

mg doxycycline hyclate delayed release tablet products made to any customers or potential customers;

PLEASE TAKE FURTHER NOTICE that Plaintiffs will rely upon the Brief in Support of Plaintiffs' Motion for a Contingent Temporary Restraining Order and Preliminary Injunction Against Mylan, the Declarations of Martyn C. Davies, Paul Herendeen, Professor Jerry A. Hausman, Roger Aston, and Brendan M. O'Malley, Esq., and the supporting exhibits to these Declarations, the Declaration and Responsive Expert Report of Professor James W. McGinity Pursuant to Fed. R. Civ. P. 26(a)(2)(B) Regarding the Validity of United States Patent No. 6,958,161, the supporting exhibits to this Declaration, and oral argument of counsel;

PLEASE TAKE FURTHER NOTICE that a Proposed Order granting Plaintiffs'

Motion for a Preliminary Injunction is attached;

PLEASE TAKE FURTHER NOTICE that a Proposed Order granting Plaintiffs'

Motion for a Temporary Restraining Order is attached.

OF COUNSEL:

Dominick A. Conde Diego Scambia Gregory B. Sephton FITZPATRICK, CELLA, HARPER & SCINTO 1290 Avenue of the Americas New York, NY 10104-3800 Phone: (212) 218-2100 Facsimile: (212) 218-2200

Attorneys for Plaintiffs
Warner Chilcott Laboratories Ireland Ltd.,
Warner Chilcott Company, LLC and
Warner Chilcott (US), LLC

Dated: August 24, 2011

By: s/ John E. Flaherty
John E. Flaherty
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
Phone: (973) 622-4444
Facsimile: (973) 624-7070

Attorneys for Plaintiffs
Warner Chilcott Laboratories Ireland Ltd.,
Warner Chilcott Company, LLC,
Warner Chilcott (US), LLC and
Mayne Pharma International Pty. Ltd.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that true and correct copies of the foregoing Plaintiffs' Notice of Motion for Preliminary Injunction and Temporary Restraining Order Against Defendants Mylan Pharmaceuticals Inc. and Mylan Inc. and supporting papers were caused to be served on August 24, 2011, via electronic mail and ECF upon the following:

Arnold B. Calmann (abc@saiber.com)

Geri L. Albin (gla@saiber.com)

SAIBER LLC

One Gateway Center, 13th Floor Newark, New Jersey 07102

Larry Shatzer (lshatzer@wsgr.com)

WILSON SONSINI GOODRICH & ROSATI

Professional Corporation 1700 K Street, NW, Fifth Floor Washington, D.C. 20006

Dieter H. Hellmoldt (dhellmoldt@wsgr.com)

WILSON SONSINI GOODRICH & ROSATI

Professional Corporation 650 Page Mill Road Palo Alto, California 94304

Jennifer Koh (jkoh@wsgr.com)

WILSON SONSINI GOODRICH & ROSATI

Professional Corporation 12235 El Camino Real, Suite 200 San Diego, California 92130

Counsel for Defendants Mylan Pharmaceuticals Inc. and Mylan Inc.

Dated: August 24, 2011 <u>s/John E. Flaherty</u> John E. Flaherty